S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
Log in
NASDAQ:PSTI

Pluristem Therapeutics Stock Forecast, Price & News

$10.67
+0.17 (+1.62 %)
(As of 12/3/2020 04:30 PM ET)
Add
Compare
Today's Range
$10.40
Now: $10.67
$10.79
50-Day Range
$8.66
MA: $9.64
$11.14
52-Week Range
$2.82
Now: $10.67
$13.29
Volume330,500 shs
Average Volume886,550 shs
Market Capitalization$273.50 million
P/E RatioN/A
Dividend YieldN/A
Beta2.59
Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
Pluristem Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.74 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PSTI
CUSIPN/A
Phone972-74-710-8600
Employees146

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20,000.00
Price / Sales13,675.21
Book Value$2.20 per share

Profitability

Net Income$-29,150,000.00

Miscellaneous

Market Cap$273.50 million
Next Earnings DateN/A
OptionableOptionable
$10.67
+0.17 (+1.62 %)
(As of 12/3/2020 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PSTI News and Ratings via Email

Sign-up to receive the latest news and ratings for PSTI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pluristem Therapeutics (NASDAQ:PSTI) Frequently Asked Questions

How has Pluristem Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Pluristem Therapeutics' stock was trading at $2.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PSTI stock has increased by 269.2% and is now trading at $10.67.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Pluristem Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pluristem Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Pluristem Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Pluristem Therapeutics?

Wall Street analysts have given Pluristem Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pluristem Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Pluristem Therapeutics' earnings last quarter?

Pluristem Therapeutics Inc. (NASDAQ:PSTI) announced its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.10.
View Pluristem Therapeutics' earnings history
.

When did Pluristem Therapeutics' stock split? How did Pluristem Therapeutics' stock split work?

Pluristem Therapeutics's stock reverse split on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2019. An investor that had 100 shares of Pluristem Therapeutics stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for PSTI?

4 analysts have issued 1-year target prices for Pluristem Therapeutics' stock. Their forecasts range from $12.00 to $16.00. On average, they anticipate Pluristem Therapeutics' stock price to reach $13.88 in the next twelve months. This suggests a possible upside of 30.0% from the stock's current price.
View analysts' price targets for Pluristem Therapeutics
.

Who are some of Pluristem Therapeutics' key competitors?

What other stocks do shareholders of Pluristem Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pluristem Therapeutics investors own include Teva Pharmaceutical Industries (TEVA), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Protalix BioTherapeutics (PLX), Micron Technology (MU), Pfizer (PFE), SCYNEXIS (SCYX) and Advanced Micro Devices (AMD).

Who are Pluristem Therapeutics' key executives?

Pluristem Therapeutics' management team includes the following people:
  • Mr. Zami Aberman, Exec. Chairman (Age 66, Pay $501.24k)
  • Mr. Yaky Yanay, Pres, CEO & Director (Age 49, Pay $350.29k)
  • Ms. Chen Franco-Yehuda, CFO, Treasurer & Sec. (Age 37, Pay $207.69k)
  • Mr. Lior Raviv, VP of Operations & Devel.
  • Ms. Efrat Kaduri, Director of Bus. Devel. & Marketing
  • Ms. Efrat Livne-Hadass, VP of HR

What is Pluristem Therapeutics' stock symbol?

Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."

Who are Pluristem Therapeutics' major shareholders?

Pluristem Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (6.82%), Nikko Asset Management Americas Inc. (0.40%), Bank Julius Baer & Co. Ltd Zurich (0.21%), California Public Employees Retirement System (0.19%), Raymond James & Associates (0.14%) and Aristides Capital LLC (0.12%). Company insiders that own Pluristem Therapeutics stock include Clover Wolf Capital - Limited, Moria Kwiat and Yaky Yanay.
View institutional ownership trends for Pluristem Therapeutics
.

Which institutional investors are selling Pluristem Therapeutics stock?

PSTI stock was sold by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Bank Julius Baer & Co. Ltd Zurich, and LPL Financial LLC.
View insider buying and selling activity for Pluristem Therapeutics
.

Which institutional investors are buying Pluristem Therapeutics stock?

PSTI stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Aristides Capital LLC, California Public Employees Retirement System, Raymond James & Associates, State Street Corp, and TFC Financial Management. Company insiders that have bought Pluristem Therapeutics stock in the last two years include Clover Wolf Capital - Limited, Moria Kwiat, and Yaky Yanay.
View insider buying and selling activity for Pluristem Therapeutics
.

How do I buy shares of Pluristem Therapeutics?

Shares of PSTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pluristem Therapeutics' stock price today?

One share of PSTI stock can currently be purchased for approximately $10.67.

How big of a company is Pluristem Therapeutics?

Pluristem Therapeutics has a market capitalization of $273.50 million and generates $20,000.00 in revenue each year. Pluristem Therapeutics employs 146 workers across the globe.

What is Pluristem Therapeutics' official website?

The official website for Pluristem Therapeutics is www.pluristem.com.

How can I contact Pluristem Therapeutics?

Pluristem Therapeutics' mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 3508409. The biotechnology company can be reached via phone at 972-74-710-8600 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.